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Image-guided multipolar radiofrequency
ablation of liver tumours: initial clinical results
Abstract The local effectiveness and
clinical usefulness of multipolar
radiofrequency (RF) ablation of liver
tumours was evaluated. Sixty-eight
image-guided RF sessions were per-
formed using a multipolar device with
bipolar electrodes in 53 patients.
There were 45 hepatocellular carci-
nomas (HCC) and 42 metastases with
a diameter ≤3 cm (n=55), 3.1–5 cm
(n=29) and >5 cm (n=3); 26 nodules
were within 5 mm from large vessels.
Local effectiveness and complications
were evaluated after RF procedures.
Mean follow-up was 17±10 months.
Recurrence and survival rates were
analysed by the Kaplan-Meier meth-
od. The primary and secondary tech-
nical effectiveness rate was 82% and
95%, respectively. The major and
minor complication rate was 2.9%,
respectively. The local tumour pro-
gression at 1- and 2-years was 5% and
9% for HCC nodules and 17% and
31% for metastases, respectively; four
of 26 nodules (15%) close to vessels
showed local progression. The survi-
val at 1 year and 2 years was 97% and
90% for HCC and 84% and 68% for
metastases, respectively. Multipolar
RF technique creates ablation zones of
adequate size and tailored shape and is
effective to treat most liver tumours,
including those close to major hepatic
vessels.
Keywords Radiofrequency ablation .
Liver . Hepatocellular carcinoma .
Metastasis
Introduction
Evidence is building up that image-guided radiofrequency
(RF) ablation has a place in the treatment of limited
hepatocellular carcinoma (HCC) in cirrhosis because it
may offer effective primary local tumour control and long-
term survival comparable with surgery in over 90% of
cases [1–3]. In more advanced tumours, RF can be used
alone or in conjunction with transarterial chemoembolisa-
tion (TACE) in order to prevent local tumour progression
[4]. Currently, available data suggest that successful
ablation of liver metastases, notably of colorectal cancer,
is more difficult to achieve than with HCC [5–9]. This is
probably due to differences in tumour conductivity and
perfusion-mediated tissue cooling of the surrounding liver
[10]. Hence, technical improvements of RF ablation are
aiming at increasing ablation zones in order to provide
adequate tumour coverage, particularly in the tumours
close to large vessels.
All major published clinical series of RF ablation of liver
tumours are based on monopolar energy deposition.
Different systems are currently available using single,
cluster or multitined expandable designs with either
internal cooling or open circuit perfusion [11]. Experi-
mental comparative studies have shown that their ability to
create large ablation zones may vary considerably [12, 13].
Bipolar energy deposition has the advantage of being more
reproducible and has been proposed to obtain large ablation
zones [14–16]. Recently, a new bipolar system has become
available for clinical use that offers bipolar and multipolar
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settings. Preliminary reports have addressed technical
feasibility and safety of this device [17, 18].
The purpose of the present study was to evaluate the
local effectiveness and the clinical usefulness of image-
guided RF ablation with this multipolar technique in
primary and secondary liver malignancies.
Materials and methods
Patients and lesions
The present study was approved by the institutional ethics
committee and was based on clinical and radiological data
of a consecutive series of 68 multipolar RF sessions for 87
malignant hepatic nodules in 53 patients, between July
2003 and June 2006. All patients were included after
informed consent was obtained. General contraindications
included prothrombin time ratio <50%, platelet count
<50,000/mm3, cirrhosis of Child class C, encephalopathy,
major ascites, bacterial infection, vascular invasion and
extrahepatic metastases.
Thirty-one patients (24 men, seven women; mean age,
65 years; range, 15–82 years) had HCC, including 19
patients (61%) with Child A cirrhosis, nine patients (29%)
with Child B and three patients (10%) without underlying
liver disease. In 24 patients, multipolar RF ablation was the
first treatment, whereas seven patients had undergone prior
treatment; hepatic resection (n=4), TACE (n=2) and
monopolar RF ablation (n=1). Forty-five HCC nodules
were diagnosed according to the European Association for
the Study of the Liver; 27 hypervascular nodules ≥2 cm by
dynamic imaging techniques and 18 hypovascular and/
or <2 cm nodules by ferucarbotran-enhanced MR imaging
or coaxial core biopsy [19]. The long-axis diameter of
index tumours was ≤3.0 cm in 27 nodules, 3.1–5.0 cm in
15 nodules and >5.0 cm in three nodules (Table 1). Eight
nodules were located within 5 mm from vessels ≥3 mm in
diameter (hepatic vein, n=5; portal branch, n=2; inferior
vena cava, n=1) [20]. Eighteen nodules were located
within 5 mm from adjacent organs (gastrointestinal tract,
n=2; gallbladder, n=2; kidney, n=1) or from the liver
capsule (n=13).
Twenty-two patients (13 men, nine women; mean age,
64 years; range, 39–88 years) had liver metastases. Sixteen
patients had 28 metastases from colorectal carcinoma; 13
patients had received systemic chemotherapy previously.
One patient had eight metastases from a gastric stromal
tumour. The five other patients had metastases from breast
cancer (n=2), lung cancer (n=1), bladder cancer (n=1) and
cholangiocarcinoma (n=2). Forty-two liver metastases
were diagnosed, either by US, CT and Mn-DPDP-
enhanced MR (n=32) or by coaxial core biopsy (n=10).
The long-axis diameter of index tumours was ≤3.0 cm in
28 nodules and 3.1–5.0 cm in 14 nodules. Eighteen
nodules were situated within 5 mm from major vessels
(hepatic vein, n=9; portal branch, n=6; inferior vena cava,
n=3), whereas ten others were located within 5 mm from
the gallbladder (n=2), the gastrointestinal tract (n=3) or the
liver capsule (n=5).
RF ablation procedures
The 68 RF treatments were performed by four experienced
radiologists in liver interventions under general anaesthesia
or short-acting intravenous sedation. Prophylactic ceftri-
axone was intravenously administered before electrode
insertion and repeated twice over 48 h. US guidance was
chosen in 56 procedures (82%) and 16-detector CT was
used in 11 procedures (16%). One small HCC nodule was
treated under MRI guidance (2%) using a 0.23-T open-
magnet and a MR-compatible electrode [21].
The bipolar electrodes (Celon ProSurge; Celon Medical
Instruments, Teltow, Germany) had a diameter of 1.8 mm,
an active tip length of 20, 30, or 40 mm and a shaft length
of 10–25 cm, and were internally cooled by means of a
pump (Celon Aquaflow III) [18]. For small nodules, one
bipolar electrode with an appropriate active tip length was
placed centrally within the tumour. For larger tumours, two
Table 1 Size of HCC nodules and metastases before RF ablation (index tumours) and corresponding ablation zone 24 h and 1month after
RF ablation. Data are mean value ± standard deviation, with ranges in parentheses; n number of nodules
Parameters Index tumour Ablation zone (24 h) Ablation zone (1 month)
HCC (n=45)
long-axis [cm] 2.4±1.0 (0.9–5.4) 4.7±1.4 (2.4–8.6) 3.7±1.2 (1.6–6.4)
short-axis [cm] 1.8±0.8 (0.7–4.8) 3.2±1.0 (1.8–5.8) 2.6±1.2 (0.9–6.9)
volume [cm3] 7.3±11.7 (0.2–68.0) 38.0±35.9 (5.5–188.0) 18.6±23.4 (0.7–120.2)
Metastases (n=42)
long-axis [cm] 2.2±0.9 (0.7–5.0) 4.9±1.3 (1.6–8.0) 3.8±1.3 (1.4–6.5)
short-axis [cm] 1.7±0.8 (0.6–4.3) 3.3±0.9 (0.9–5.0) 2.5±0.9 (0.9–4.2)
volume [cm3] 6.3±9.7 (0.1–55.2) 41.1±25.7 (0.9–108.9) 17.8±13.0 (0.9–48.0)
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or three electrodes were placed in parallel in the outer third
of the nodule (Fig. 1). The mean distance between the
electrodes was 1.6±0.7 cm (range, 0.9–2.6 cm). One
electrode was used in 24 (28%) of the 87 ablations,
two electrodes in 42 ablations (48%) and three electrodes in
21 ablations (24%). Whenever a tumour was in the vicinity
of a large vessel or an extrahepatic organ, at least one
electrode was placed between the tumour and related
structure (Fig. 2). The puncture time was defined as the
time from the skin puncture to the final evaluation of
electrodes positioning.
RF ablations were performed with a 470-kHz RF
generator (CelonLab Power), which can manage simulta-
neously up to three bipolar electrodes by automatic
impedance-feedback [18]. The initial power output was
chosen between 20 and 150 W (mean, 65±34 W),
depending on tumour size and number of electrodes. The
endpoint of energy deposition was based on empirical
parameters, taking into account the tumour type, size and
geometry. These parameters were monitored by a dedicated
software (CelonPower Monitor). In a large HCC nodule
with mixed vascularity, selective TACE of the hypervas-
cular portion was done before RF ablation of the
Fig. 1 Large hepatic metastasis from bronchogenic carcinoma close
to the right kidney in a 53-year-old male after left pneumectomy.
The patient refused hepatic resection. a Fast spin-echo T2-weighted
MR image obtained before RF ablation shows a large (long-axis
diameter, 5.0 cm; volume, 55 cm3) and heterogeneously hyperintense
mass in segment 6 close to median portion of the right kidney (white
arrows). b Ultrasound scan obtained during the placement of three
bipolar RF electrodes with 4-cm active tips. The first and second
electrodes are positioned at the lateral border of the tumour, in an
anterior and posterior fashion respectively. A third electrode (not
shown) was placed between the medial border of the tumour and the
right kidney. c Contrast-enhanced CT scan obtained during portal
phase 24 h after RF ablation (power output, 100 W; duration, 45 min;
total applied energy, 235 kJ) shows that the index tumour is
completely covered by the ablation zone (long-axis diameter, 6.8 cm;
volume 105 cm3) with an ablative margin larger than 5 mm. No lesion
of the right kidney is observed. d Fast spin-echo T2-weighted MR
image obtained at 7 months after RF ablation shows the ablation zone
with low signal intensity (white arrows) without detectable residual
tumour
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hypovascular zone [22]. Intraductal cooling by cold saline
through a percutaneously placed 20G Chiba needle was
performed during RF ablation of a HCC nodule close to left
hepatic duct [23]. Gray-scale US imaging was used for
monitoring of the transient hyperechoic zone. Contrast-
enhancement with microbubbles was performed immedi-
ately after six procedures. Three CT-guided procedures were
done with intravenous contrast media. For the small nodule
ablated under MRI guidance, T2-weighted images were
used to evaluate treatment response. A second exposure was
achieved in two ablations after electrodes repositioning.
Track coagulation was performed with each electrode
separately. Post-procedural imaging was achieved in order
to detect immediate complications. The procedure time,
including electrodes placement and removal, RF ablation
and imaging control, was recorded. After RF ablation, all
patients stayed in the hospital overnight for medical
observation and laboratory; they were discharged after
recovery from sedation or any complication. Symptoms of
post-ablation syndrome were recorded during the hospital
stay and at the one month visit.
Follow-up and image analysis
Description of the results of RF ablation was based on
recommendations by the International Working Group on
Image-Guided Tumor Ablation [24]. Twenty-four hours
after RF procedure, the technical success and early
complications were assessed by a triphasic contrast-
enhanced CT with the following parameters: 2 ml/kg of
iodinated contrast agent, rate of 3–5 ml/s, section thickness
3.0 mm, reconstruction interval 1.5 mm. Any preexisting
tumour region not covered by the ablation zone was
considered as residual tumour. If the ablation zone was
ellipsoid, its volume was derived from its three orthogonal
diameters along the electrodes axis on the portal phase
images. If the ablation zone was irregular, an institutional
software calculated the volume by three-dimensional
watershed algorithm [25]. Ablative margins were evaluated
by image fusion in the axial and coronal planes.
One month after treatment, technical effectiveness was
assessed by using contrast-enhanced CT for hypervascular
nodules and hepatospecific contrast-enhanced MRI for
Fig. 2 Small hepatic metastasis
from colorectal carcinoma close
to the inferior vena cava (IVC)
in a 57-year-old male after right
hepatectomy. a Fast spin-echo
T2-weighted MR image ob-
tained before RF ablation shows
a mildly hyperintense nodule
(long-axis diameter, 1.9 cm;
volume, 2.9 cm3) in contact with
the medial border of the IVC
(white arrows). b Unenhanced
CT scan obtained just before RF
ablation (power output, 35 W;
duration, 27 min; total applied
energy, 51 kJ) shows the place-
ment of two bipolar electrodes
with a 3-cm active tip. The first
electrode was positioned be-
tween the IVC and the tumour
and the second one was posi-
tioned on the medial side of the
tumour. c Contrast-enhanced CT
scan obtained during portal
phase immediately after RF
ablation shows that the index
tumour is completely covered
by the ablation zone (maximal
diameter, 5.3 cm; volume
52 cm3) with an ablative margin
larger than 10 mm. The IVC is
still patent. d Contrast-enhanced
CT scan obtained during portal
phase 17 months after RF
ablation shows that the ablation
zone has undergone involution,
without evidence of local
tumour progression
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hypovascular nodules. Any contrast-enhanced foci on CT
and hyperintensity on T2-weighted images or non-enhanc-
ing area on contrast-enhanced MR images at the bound-
aries of the treated area was considered as incomplete
ablation. Follow-up consisted in monitoring of tumour
markers and CT or MRI scans every 3–4 months, and
results were recorded according to standard criteria [24,
26]. Recurrence rates were calculated from the first RF
ablation to the imaging follow-up that revealed tumour
progression. Survival data were calculated from the first
RF treatment to the time of death or analysis (September
2006). Local tumour progression and new tumours nodules
prompted additional RF ablation, if the patient still met the
requirements.
Statistical analysis
Descriptive statistical measures, including mean values,
standard deviations and ranges, were calculated for the
ablation zone sizes. The relationship between ablation zone
volume and applied energy was analysed by Pearson
correlation analysis. The difference between ablative
margins between HCC and metastases were analysed by
The Mann-Whitney U-test. Local tumour progression and
survival rates were estimated by the Kaplan-Meier method
and the curves were compared with the log-rank test. A P
value of less than 0.05 was considered as a statistically
significant difference. Statistical analysis was performed
with a commercial software (JMP version 6.0 for MacOsX;
SAS Institute, Cary, USA).
Results
RF ablation procedures
RF ablation with complete tumour coverage was achieved
in 86 of the 87 malignant nodules for a technical success
rate of 99%. In one patient with advanced macronodular
cirrhosis, one of the multiple benign nodules had been
ablated under US guidance, instead of the malignant HCC
nodule. Complete ablation was obtained after a second RF
session. The mean puncture time per tumour was 15±6 min
(range, 3–36 min) using US, 31±9 min (12–58 min) using
CT (P=0.009), and 73 min for the nodule treated under MR
guidance. The mean ablation time per tumour was 29±
10 min (10–50 min). The mean procedure time was 67±
34 min (39–132 min) with US, 128±51 min (54–221 min)
with CT (P=0.031) and 202 min with MR guidance. A
mean total energy of 61±46 kJ (range, 11–215 kJ) was
applied per HCC nodule and 75±44 kJ (13–235 kJ) per
metastasis.
No procedure-related death was observed. Two major
complications (2.9%) occurred among the 68 procedures.
In a patient with a subcapsular HCC of the hepatic dome, a
right pneumothorax occurred during electrodes position-
ing. A chest tube was immediately placed, the RF
procedure was continued and CT showed complete reso-
lution of the pneumothorax after 48 h. One case of
electrode tract seeding was identified after treatment of a
subcapsular HCC, although a route through liver paren-
chyma had been chosen. A 4.2-cm hypervascular nodule
was found on 6-month CT in the greater omentum and
resected surgically. Minor complications were observed in
two (2.9%) of 68 procedures. A partial right portal vein
thrombosis was successfully treated with oral acenocou-
marol during 4 weeks. A small second-degree skin burn at
the puncture site completely resolved after application of
silver sulphadiazine cream. Side effects were observed in
13 (19%) of the 68 procedures, including asymptomatic
pleural or peritoneal effusion (n=8), and self-limited
subcapsular or peritoneal bleeding (n=5). Postablation
syndrome occurred after 19 (28%) of 68 RF sessions;
symptoms peaked on day 2 and always resolved within
8 days with nonsteroidal anti-inflammatory drugs. The
mean duration of hospitalisation was 2.1±1.2 days (range,
1–5 days). Forty-four patients (83%) were discharged after
overnight observation. Six patients (11%) stayed an
additional night for observation of post-ablation syndrome
and three patients (6%) stayed longer for treatment of
complications (n=3).
Ablation zone size and shape
The size of the ablation zone 24 h and one month after RF
ablation is presented in Table 1. At 24 h, the difference
between the mean long-axis and short-axis diameters of
ablation zone and the index tumour was on average 2.3 cm
and 1.4 cm for HCC nodules, and 2.7 cm and 1.6 cm for
metastases, respectively. The ablation zone volume 24 h
after RF ablation was five- to six-times larger than the
index tumour volume and there was substantial involution
1 month after treatment. The maximum ablation zone
achieved was 8.6×7.2×5.8 cm (188 cm3) in a HCC nodule
and 8.0×5.2×5.0 cm (109 cm3) in a metastasis. The mean
ablation zone volume achieved with one, two and three
electrodes was 15.0±11.5 cm3, 34.1±18.0 cm3 and 75.6±
37.1 cm3, respectively. In the HCC group, the ablation zone
volume showed a close correlation with the applied energy
(Fig. 3a). In the metastasis group, this correlation was less
strong, which is probably due to the outlier metastasis to
the right of the graph (Fig. 3b). Sixty-eight (78%) of the 87
ablation zones were concentric with regard to index
tumour, whereas 19 ablation zones (22%) were eccentric
but completely covering the tumour. Ablative margins
were ≥5 mm in 78 (90%) of 87 ablation zones and
≥10 mm in 51 (59%) of 87 ablation zones (Table 2). No
statistically significant difference was found between
ablative margins of ≤3 cm and >3 cm nodules, and
between HCC and metastatic nodules.
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Follow-up
At 1-month imaging, complete tumour ablation was
depicted in 85(98%) of 87 nodules. The extra-hepatic
portion of a subcapsular HCC was not totally ablated and,
in another patient, the ablation zone of a metastasis showed
residual tumour. On subsequent follow-up, local tumour
progression was observed in four HCC nodules and in ten
metastases. It is noteworthy that none of the eight HCC
nodules close to a major vessel showed local tumour
progression. In metastases, the rate of local tumour
progression was 22% (4/18) in nodules adjacent to large
vessels and 25% (6/24) at distance from them. Complete
tumour destruction after one RF session was achieved in 71
of 87 malignancies for a primary effectiveness rate of 82%.
Since 12 of the 16 tumours with local tumour progression
were retreated with RF and resulted in complete ablation,
the secondary technique effectiveness rate was 95%. Two
patients with residual hypervascular HCC underwent
selective TACE. One patient with two local and multiple
new recurrences was treated by chemotherapy.
The mean follow-up period was 17.1±10.0 months
(range, 3.3–37.7 months). The 1-and 2-year local tumour
progression rates were 5% and 9% for HCC nodules, and
17% and 31% for metastases, respectively (P=0.032)
(Fig. 4). The recurrence rates of new tumours at 1 and
2 years were 16% and 29% for HCC, and 33% and 58% for
metastases, respectively (P=0.047). The overall recurrence
rates were 20% and 36% for HCC, and 42% and 79% for
metastases, respectively (P=0.041).
At the end of the study, three of 31 patients of the HCC
group had died from liver failure with tumour progression,
liver failure without tumour progression and myocardial
infarction. At the end of the study, eight of 22 patients with
liver metastases had died. Six patients died from metastatic
disease and two patients died from urosepsis and hemor-
rhagic stroke. The overall survival rates for the patients
with HCC were 97% at 1 year and 90% at 2 years; the
median follow-up was 18.1 months (Table 3). The overall
survival rates for the patients with metastases were 84% at
1 year and 68% at 2 years; the median follow-up was
20.8 months. The difference between the survival curve for
patients with HCC and patients with metastases was
statistically significant (P=0.038).
Discussion
Multipolar RF ablation with the simultaneous use of one or
more bipolar electrodes has the potential advantage to create
larger ablation zones compared with sequential use of
monopolar electrodes with repositioning. Since the alter-
nating current is confined to the area under treatment, this
Table 2 Ablative margins of the ablation zones after RF ablation for HCC nodules and metastases (n number of nodules)
n Ablative margin <5 mm Ablative margin 5–10 mm Ablative margin >10 mm
HCC≤3 cm 27 4 (15%) 9 (33%) 14 (52%)
HCC>3 cm 18 2 (11%) 7 (39%) 9 (50%)
Metastases≤3 cm 28 3 (11%) 7 (25%) 18 (64%)
Metastases>3 cm 14 0 (0%) 4 (29%) 10 (71%)
All 87 9 (10%) 27 (31%) 51 (59%)
Fig. 3 Graphs show relationship between the volume of the
ablation zone in cm3 and applied energy in kJ. a In the HCC group,
an increase in applied energy produced an increase in volume (R2=
0.747), as determined by V=0.760XE+6.157, where V is volume
and E is applied energy. b In the metastases group, the regression
line equation was V=0.552XE+10.071 (R2=0.687). If the outlier to
the right of the graph is eliminated, the correlation is better (R2=
0.718)
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approach also permits to avoid adverse events inherent to the
monopolar technique, such as unpredictable electrical
current paths, heterogeneous energy deposition and skin
burns at the grounding pad [15, 27–29]. Although the
technical aspects of multipolar RF ablation have been
addressed, published clinical experience with percutaneous
use of this technology is still limited [18, 30]. The data of
our study confirm that the multipolar technique is feasible in
a clinical procedure of reasonable duration using either US
or CT targeting. Although MR guidance is also feasible, the
procedural time is still quite excessive. Despite the use of
multiple electrodes in the majority of procedures, the rate of
complications was no higher than from series with mono-
polar devices [1, 2, 7, 8, 31–33]. It is noteworthy that most
adverse events had occurred in lesions protruding from the
liver contour, which are recognised as a risk factor for
complications, including electrode track seeding [34].
The size of the ablation zone correlated with the amount
of deposited energy for both HCC and metastases.
Although the difference was not significant, total energy
deposition was greater in metastases than in HCC,
depending on tissue impedance and perfusion-mediated
tissue cooling. Therefore, applied energy in metastases
should be about 40% greater to obtain the same volume
than HCC nodules. The creation of ablation zones with at
least a 5 mm margin was possible without electrodes
repositioning in the vast majority of cases. A single bipolar
electrode is sufficient for complete coverage of nodules
less than 1.5 cm, but we recommend two or more
electrodes for larger nodules. When multiple electrodes
are used, they should be placed in a parallel fashion, in
order to obtain an ovoid ablation zone. When treating
tumours that are adjacent to major vessels or extrahepatic
organs, at least one electrode should be placed between the
involved structure and the tumour periphery. In that
configuration, the tumour are “in brackets” between the
electrodes. It is noteworthy that 22 (85%) of the 26 tumour
nodules close to large vessels were ablated without local
progression. In an animal experiment using bipolar RF
ablation, it had been demonstrated that heat sink effect was
decreased and tumour cell survival next to vessels was
reduced [35].
Published results from ex-vivo studies indicated that
multipolar RF ablation enables larger ablation zones to be
Fig. 4 Graph shows local tu-
mour progression rates of HCC
nodules (continuous lines) and
metastases (dotted line). The
numbers of tumours followed-
up for 6, 12, 18, 24 and
30 months were 43, 30, 23, 17
and 7 for HCC nodules, and 32,
24, 19, 10 and 7 for the metas-
tases, respectively. The 1- and
2-year local tumour progression
rates were 5% and 9% for HCC
nodules, and 17% and 31%
for metastases, respectively
(P=0.032)
Table 3 Overall survival rates for
patients with HCC and
patients with liver metastases
(nnumber of patients followed-up)
Time (months) HCC Metastases
n Survival (%) n Survival (%)
0 31 100 22 100
6 30 97 19 95
12 18 97 17 84
18 14 90 15 74
24 12 90 8 68
30 6 79 5 60
36 3 79 0 –
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obtained than with monopolar devices [12, 13, 36, 37].
This observation was confirmed by other in-vivo experi-
ments in pig liver, especially with regard to the heat sink
effect [35, 38, 39]. Although a direct clinical comparison
between multipolar and monopolar RF techniques is
crucial, it was beyond the scope of the present study. The
limitations of our study were the small number of
histologically confirmed metastases, as well as the limited
follow-up time with regard to tumour progression and
survival. Nonetheless, our current data regarding treatment
of HCC compare favourably with other published series
when comparing tumours of similar size [2, 40–43]. The
results of RF treatment of metastatic nodules are much
more difficult to compare because of histologic stratifica-
tion, tumour size, concomitant chemotherapy regimens and
previous surgical therapy [5–9]. While almost one-third of
nodules treated in our series were within 5 mm from large
vessels, most clinical reports on liver RF ablation have
failed to mention the anatomic vicinity of hepatic vessels.
In conclusion, the multipolar technique is effective in
producing ablation zones of adequate size and according to
individual tumour geometry in the majority of primary and
secondary liver tumours, including tumours close to major
hepatic vessels. The use of multiple electrodes does not
seem to increase the risk of complications compared with
previously reported series.
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